Board of Directors
Jay R. Luly, Ph.D.
President, Chief Executive Officer and Director
Dr. Jay Luly has been leading Enanta since July 2003, having successfully navigated and grown Enanta through its venture-financed years, its successful IPO in 2013, and three major collaborations delivering over $1 billion in non-dilutive financing to date. Under Dr. Luly’s leadership, Enanta collaborated with AbbVie in the discovery and development of two novel hepatitis C virus protease inhibitors: glecaprevir and paritaprevir, which are part of the combination regimens commercialized as MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) and VIEKIRA PAK®, respectively. MAVYRET (glecaprevir/pibrentasvir) which was approved by the FDA in 2017, requires only eight weeks of treatment, the shortest duration of any hepatitis C regimen.
Prior to joining Enanta, Dr. Luly was an Entrepreneur in Residence at Oxford Bioscience Partners. Previously, Dr. Luly held the positions of Senior Vice President, Research and Development Operations and Senior Vice President, Discovery Strategy and Operations at Millennium Pharmaceuticals following Millennium’s acquisition of LeukoSite, Inc. in 1999. Dr. Luly had served as Senior Vice President, Drug Discovery and Preclinical Development at Leukosite, prior to which he held several senior drug discovery positions at Abbott Laboratories from 1983 to 1997.
Dr. Luly received a B.S. in Chemistry from the University of Illinois, Urbana/Champaign and a Ph.D. in Synthetic Organic Chemistry from the University of California, Berkeley.